Rajni Agarwal, MD
Pediatric Medicine · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Agarwal’s office at (650) 498-7200 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence C50583 · Current
Licensed to practise in California · since 2001 · expires 2027-01-31 · Indore University, M. G. M. Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$1,125 in 2023
Medicaid paid $1,125 for 33 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Service | 33 | $1,125 |
| 2023 | 33 | 1 | 12 | $1,125 |
Money from drug and device companies
$1,407 in 2024
| 2024 | 1 | 1 | None | $1,407 |
| 2020 | 3 | 15 | $7,000 | $8,507 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Celgene | None | $1,407 | 1 payment
|
See the published payment
| Celgene | Travel · 2024-03-21 | None | $1,407 |
See earlier years (2020)
2020: $8,507
| Jazz Pharmaceuticals | Vyxeos | $8,471 | 13 payments
|
| Amgen | Aimovig | $23 | 1 payment
|
| Zyla Life Sciences | Sprix | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| JAZZ PHARMACEUTICALS INC. · A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide Vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant · 2019 | Their institution | $188,923 |
| JAZZ PHARMACEUTICALS INC. · A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide Vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant · 2021 | Their institution | $19,782 |
| Jazz Pharmaceuticals Inc. · A Phase 3, Randomized, Adaptive Study Comparing the Efficacy Andsafety of Defibrotide Vs Best Supportive Care in the Prevention Ofhepatic Veno-Occlusive Disease in Adult and Pediatric Patientsundergoing Hematopoietic Stem Cell Transplant · 2020 | Their institution | $10,818 |
| JAZZ PHARMACEUTICALS INC. · A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide Vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant · 2020 | Their institution | $7,040 |
Professional record
- NPI
- 1053455535
- Licence
- CA C50583California C50583: Current · expires 2027-01-31
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X)
- Mailing address
- 300 Pasteur Dr, Peds Phys Billing Mc 5530, Stanford, CA, 94305
- NPI first listed
- 2007-02-16
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305